The Feline IFN alpha polyclonal antibody is unlabeled and has been qualified for use in ELISA and Western blot applications. It is the capture antibody in the Kingfisher Feline IFN alpha ELISA. The Feline IFN alpha antibody was produced in rabbits and is antigen-affinity purified. The reactivity by species is: (Bovine IFN-alphaA - None) (Canine IFN-alpha - None) (Caprine IFN-alpha - None) (Chicken IFN-alpha - None) (Equine IFN-alpha1 - None) (Feline IFN-alpha - Strong) (Human IFN-alpha - None) (Mouse IFN-alpha - None) (Ovine IFN-alpha - None) (Swine IFN-alpha1 - None). For research use only.
Feline Interferon-Alpha (IFN-α) is a type I interferon produced primarily by plasmacytoid dendritic cells and virus-infected cells in cats (Felis catus), where it plays a central role in innate antiviral immunity by inducing interferon-stimulated genes (ISGs), enhancing antigen presentation, and activating natural killer (NK) cells and adaptive immune responses through the IFNAR receptor complex and JAK/STAT signaling pathways. In feline health, IFN-α is critically involved in host defense against viral infections such as feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), feline infectious peritonitis (FIP; caused by feline coronavirus), feline herpesvirus, and calicivirus, and recombinant feline IFN-α has been used therapeutically to modulate antiviral and immune responses. Dysregulated or insufficient IFN-α responses can contribute to viral persistence, immunopathology, or chronic inflammation. Importantly, cats serve as valuable natural animal models for human retroviral infections (FIV as a model for HIV), coronavirus-associated immune dysregulation (FIP as a model for severe systemic coronavirus disease), and certain oncogenic viral conditions, making characterization of feline IFN-α highly relevant for understanding antiviral immunity, viral immune evasion, and interferon-based therapeutic strategies in both veterinary and comparative biomedical research.